IVI in the Media

Maeil Business Newspaper | All music is beautiful in its own way, but Violinist Sang Hee Lee’s music shines a special light

Nature | Six months of COVID vaccines: what 1.7 billion doses have taught scientists

Asian Boss | We Asked Top Vaccine Expert About COVID Vaccine Problems

Bloomberg | Consequences of ‘Huge’ Global Gap in Vaccinations

EIU Perspectives | What does Denmark’s permanent suspension of both the AstraZeneca and Janssen covid-19 vaccines mean for other countries?

Asia Times | Vaccinations in a race against viral variants

Nature | Why COVID vaccines are so difficult to compare

DEVEX | Opinion: COVAX — too big, and too important, to fail

CNN | “Our response needs to be clear, strong, and unified”

South China Morning Post | Coronavirus vaccines will save 2021? Not so fast, here’s what the experts think

Bloomberg | Will the Covid-19 Vaccines Be Effective and Safe?

Asian Boss | Update On COVID-19 Vaccine Price & Schedule From A Leading Vaccine Expert

The Telegraph | ‘If you are not prepared, the virus has found every weakness’: How countries in Asia tamed Covid-19

CGTN | ‘The vaccine itself is not the silver bullet,’ says International Vaccine Institute

Devex | Q&A: Why Jerome Kim is ‘hopeful’ but cautious about distributing a COVID-19 vaccine

Maeil Business Newspaper | IVI Director General Jerome Kim Shares His Thoughts on Resurgence of COVID-19 Outbreaks in S. Korea

Chosun Ilbo | IVI Director General Jerome Kim Shares His Thoughts on Equitable Access of COVID-19 Vaccines

Channel News Asia | On a fast track like never before: The COVID-19 vaccine effort and 5 vital questions

The Economist’s Future of Healthcare Insight Hour | Vaccine development: A race to the finish line

Devex | Q&A: Is COVID-19 helping or hindering progress toward an HIV vaccine?

TED | The trials, tribulations and timeline of a COVID-19 vaccine

Wired Korea | The End of World War C: Peace without Victory?

Asian Boss | World’s Leading Vaccine Expert Fact-Checks COVID-19 Vaccine Conspiracy

Development Today | Why Sweden funds a vaccine institute in Korea and not Oslo-based CEPI

CNBC | Parts of Asia that relaxed restrictions without a resurgence in coronavirus cases did these three things

The Korea Herald | [Herald Interview] ‘Making vaccines accessible is biggest COVID-19 challenge’

CGTN: The Agenda with Stephen Cole | Speed of vaccine trials is ‘unprecedented’

Asian Boss | We Asked The World’s Leading Vaccine Expert About COVID-19 Vaccine

The Guardian | Test, trace, contain: how South Korea flattened its coronavirus curve

BBC World Service: The Inquiry | How do we come out of the lockdown? (13:00)

ANC 24/7 | Int’l Vaccine Institute: 12-18 months reasonable timetable for development of Covid-19 vaccine

Seeker | How Fast Can We Make a Coronavirus Vaccine?

Education City Speaker Series: Flattening the Curve – Global Responses to COVID-19

Wion News | About 70% of vaccines used around the world are made in India: S Korean expert Dr Jerome Kim

South China Morning Post | How long will a coronavirus vaccine take? A Q&A with Jerome Kim, head of the International Vaccine Institute

BBC World News | Jerome Kim: Vaccines are the long-term solution to the pandemic

The Korea Times | Developing vaccine against COVID-19

TRT: Bigger than Five | COVID-19: The World Reacts

South Korea’s fight against coronavirus (CBS News)

NDTV | Top South Korea Doctor On Why He Thinks Coronavirus Is Not A ‘Chinese Virus’

RTE | What South Korea can teach Ireland about fighting Covid-19

Physical distancing should last months, not weeks, says epidemiologist (Yahoo News Canada)

Development of vaccine requires massive investment… international cooperation is needed (Korea Economic Daily)

COVID-19 Pandemic (Arirang TV, 22:50~46:00)

By then, we’ll have a vaccine on our side (Hankyoreh—Korean)

Coronavirus Pandemic: International Vaccine Institute director on how long it will take to develop vaccine (CGTN)

Testing times: Why South Korea’s COVID-19 strategy is working (Al Jazeera English)

Genexine seeks to compress the vaccine timeline

Genexine, Binex to develop COVID-19 vaccine (Korea Biomedical Review)

Genexine, Binex to co-develop coronavirus vaccine GX-19 (Korea Herald)

How close are we to a COVID-19 vaccine? Jerome H. Kim from International Vaccine Institute (Arirang News)

COVID-19 vaccine, drugs on fast track for development: IVI chief (Yonhap News)

Inside the race to find a coronavirus vaccine (Devex)

Chinese students keen for turnaround (China Daily)

China Daily | S. Korea can try out makeshift hospitals, experts say

Director General Jerome Kim for Phoenix TV

Speed and accuracy vital for COVID-19 test kits (Arirang News)

2020 COVID-19 Live Updates: Jerome Kim for tbs eFM

Jerome Kim for KBS WORLD Radio, Korea24 on the COVID-19 outbreak in South Korea

Korea should join efforts in vaccine development to prevent pandemics (JoongAng Ilbo)

Future global health threats

IVI: COVID-19 could linger (Korean)

Jerome Kim for Korea, Factual: “Hong Kong’s handling of COVID-19 outbreak & Prospects of vaccine development”

Concerns about the spread of COVID-19: When will a vaccine be developed? When can we expect the “Super Vaccine”?

Al Jazeera English | Scientists call for global cooperation over coronavirus

When will COVID-19 vaccine be commercialized…And “super vaccine”? (Korean)

Global push to find vaccine against devastating bug growing

IVI receives $15.7 million to conduct Ph III trials of typhoid vaccine

Korean vaccines expanding global territory

Neglected Victims of Neglected Diseases

Let’s build a common defense against epidemics

Vaccine investment brings 16-fold return… partnering with Bill Gates

World must join forces to prevent infectious diseases

IVI editorial in The Korea Herald advocates for Korean leadership for global health

×

DCVMN and IVI announce international cooperation over five years to strengthen and facilitate collaborations among developing c

Author
Hong
Date
2013-03-25 00:00
Views
4718

DCVMN and IVI announce international cooperation over five years to strengthen and facilitate collaborations among developing countries vaccine manufacturers


 


March 14, 2013, Shanghai, China — The Developing Countries Vaccine Manufacturers Network (DCVMN) and the International Vaccine Institute (IVI) have announced today their intentions to strengthen and facilitate collaborations among developing countries vaccine manufacturers, to achieve the common goal of protecting people against known and emerging infectious diseases by enhancing the quality and increasing the availability of vaccines in developing countries.


 


DCVMN and IVI have been working together for many years and wish to strengthen collaboration by sourcing the development, coordination and delivery of training related to vaccine research and development, manufacturing technology, and clinical and regulatory activities.


 


The two organizations share the vision of rendering developing countries free of suffering from infectious diseases, and aim to work together to foster the discovery, development and delivery of safe, effective and affordable vaccines for the world’s developing nations.


 


The global population of over 7 billion is growing at the fastest rate in developing countries, where vaccines are most needed. DCVMN, with partners such as IVI, wishes to take up this challenge of providing vaccines to all. Asia is the most populous continent, with 4.2 billion inhabitants accounting for over 60% of the world’s population. The two most-populated countries, China and India, together constitute about 37% of the world's population. Africa is the second most-populated continent, with around 1 billion people, or 15% of the world's population. Twenty-seven members of the Network are located in the Asia Pacific region and dedicated to the well-being of children.


 


“In engaging with IVI we intend to create an enabling environment for people to live long and healthy lives, free of vaccine preventable infectious diseases, and support the industry to provide continuing education to professionals for sustainable manufacturing excellence” said Dr. Mahendra Suhardono, DCVMN President. “With 38 members of our Network we represent the largest association of vaccine manufacturers globally, and together we can reach out to every child,” he added.


 


DCVMN plans to initiate a Continuing Educational Program for professionals engaged in vaccine manufacturing as one component of a comprehensive initiative that aims to provide training on quality management and GMP compliance.


 


“The partnership with DCVMN is a great step forward in realizing IVI’s vision of developing countries free of suffering from infectious diseases,” said Dr. Christian Loucq, Director-General of IVI. “IVI has a history of working with vaccine manufacturers, particularly in Asia, in manufacturing technology and clinical and regulatory activities so we look forward to a close collaboration with DCVMN in order to help us make a greater impact on improving the health of the poorest people through vaccines.”


 


About DCVMN


The Developing Countries Vaccine Manufacturers Network (“DCVMN”), envisions to protect people against known and emerging infectious diseases globally by increasing the availability and enhancing the quality of vaccines produced in developing countries, by working to strengthen vaccine manufacturers through the provision of technical assistance, training and encouraging technology transfer initiatives, innovative research, facilitating information sharing, and educating the public about the availability of safe and effective vaccines from developing countries manufacturers. The Developing Countries Vaccine Manufacturers Network (DCVMN) is a unique model of public and private international alliance assembling governmental and private vaccine manufacturers towards a common goal of supplying high quality vaccines at affordable prices. Its purpose is to protect people against known and emerging infectious diseases globally by increasing the availability and improving the quality of vaccines produced by emerging country manufacturers. For more information about DCVMN, please visit www.dcvmn.org.


 


About IVI


The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 30 countries of Asia, Africa and Latin America on vaccines against diarrheal infections, bacterial meningitis and pneumonia, as well as Japanese encephalitis and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit www.ivi.int.

DONATE